Herpes zoster vaccine reduces risk of dementia in study of 1.5 million elderly people

A shingles vaccine, already recommended for many adults over 65, has been shown to significantly reduce the risk of dementia. The finding comes from research with more than 1.5 million Medicare beneficiaries in Estados Unidos and was published in the magazine Alzheimer’s & Dementia. Vaccinated Pessoas were 33% less likely to be diagnosed with dementia during a follow-up period of up to three years.
The analysis compared 502,845 people who received both doses of the Shingrix vaccine with 1,005,690 unvaccinated people. 28% lower Risco was also observed for Alzheimer disease, and 33% lower for vascular dementia. Pesquisadores emphasize that these results come from health records and have yet to rule out other possible explanations.
Primeira routine vaccine associated with brain protection
Scientific interest in shingles vaccines for dementia was born from a clear biological observation. The varicella-zoster virus remains latent in the body for decades after initial infection. Reactivated Quando causes herpes zoster, a painful disease that triggers inflammation and neurological complications. Pesquisadores investigate whether preventing this reactivation also protects brain tissue.
A previous study published in Nature used data from País from Gales, where the vaccination campaign created a well-defined age limit. Eligible Pessoas were compared with vaccine-ineligible individuals of nearly identical age. Esse design reduces a common problem in vaccine research: healthier people tend to get vaccinated. The Welsh study found a 20% lower relative risk of a new diagnosis of dementia over seven years in those who received the live attenuated vaccine.
The Medicare data analyzed Shingrix, the newer recombinant version now widely used. Conjuntamente, both studies provide researchers with a more solid basis for testing whether the link between vaccination and reduced dementia is causal and not just association.
Mecanismos still under investigation
Cientistas propose two possible explanations for brain protection. Vacinas may reduce infections that cause inflammation in the brain. Alternativamente, can modify general immune response, making the body less likely to generate harmful inflammation as it ages. Nenhuma of the explanations has been proven so far in direct cause-and-effect studies.
A recent review by Gavi identified several large observational studies that linked vaccination in adults with a lower risk of dementia. More robust Evidências involve vaccines against shingles, influenza, respiratory syncytial virus, pneumococcus and DTP. Próximo step involves further research with clinical trials demonstrating whether vaccination reduces risk of dementia.
Vacinas specific to Alzheimer are in initial testing
Independentemente of shingles findings, researchers test vaccines designed to attack Alzheimer biology of the disease itself. Progresso on this front remains in very early stages of development. Dois lead candidates are in clinical trials at ClinicalTrials.gov:
- AV-1959R: experimental vaccine targeting amyloid beta protein. Ensaio Fase 1 studies safety, tolerability and immune response in healthy adults aged 40 to 60 years
- AV-1980R: vaccine targeting tau protein, tested in adults aged 65 to 80 years with biomarker signs of preclinical Alzheimer but without cognitive symptoms
Ensaios Fase 1 are initial human studies designed to verify safety and measure expected immunological response. Não demonstrate whether the vaccine prevents dementia in the general population. Dementia vaccine Aprovação or Alzheimer does not exist yet. Recent Dados on herpes zoster do not change this current scenario, although they reinforce the importance of investigating routine vaccines from a neurological perspective.
The research points to a new direction in preventing cognitive decline in the elderly: vaccines already used for other diseases may offer additional brain protection as an unintended benefit. Porém, scientists warn that observational studies need to be complemented with randomized controlled trials to establish causality before any specific recommendation for dementia vaccination.






